Pharmaceutical composition for soft contact lenses

By adding low concentrations of alkyldiaminoethylglycine hydrochloride to the drugs for soft contact lenses and using metal chloride, the adsorption problem of alkyldiaminoethylglycine on soft contact lenses was solved, and the drug was improved stability and safety reduce discomfort.

CN114786650BActive Publication Date: 2024-12-03SENJU PHARMA CO LTD
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202080082048.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-11-29
Filing Date
2020-11-26
Publication Date
2024-12-03
Estimated Expiration
2040-11-26

AI Technical Summary

Technical Problem

The adsorption of alkyldiaminoethylglycine on soft contact lenses in existing soft contact lenses leads to discomfort and stability problems, and the side effects of preservatives are difficult to avoid.

Method used

Add low concentration of alkyldiaminoethylglycine hydrochloride to the pharmaceutical composition for soft contact lenses and inhibit the softening of metal chlorides, especially alkali metals and group IIA metals, by mixing them with chlorides of metals, especially alkali metals and group IIA metals. Adsorption of sexual contact lenses.

Benefits of technology

It effectively inhibits the adsorption of alkyldiaminoethylglycine on soft contact lenses, reduces cytotoxicity, and improves the stability and safety of the pharmaceutical composition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The present invention aims to provide a pharmaceutical composition for soft contact lenses that inhibits adsorption of alkyldiaminoethylglycine to soft contact lenses. The pharmaceutical composition for soft contact lenses of the present invention contains 0.001 w / v% to 0.008 w / v% of alkyldiaminoethylglycine hydrochloride and a metal chloride.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition for soft contact lenses which inhibits adsorption of alkyldiaminoethylglycine to soft contact lenses. Background Art

[0002] In order to reduce the discomfort when wearing soft contact lenses or hard contact lenses, various pharmaceutical compositions for soft contact lenses with tear-like components have been studied. Tears are a mixture of more than four substances secreted from the accessory lacrimal glands in the lacrimal gland secretion from the main lacrimal gland, including Na, K, Ca, Cl, etc. as inorganic components, and glucose, ascorbic acid, citric acid, urea, ammonia, amino acids, proteins, etc. as organic components. Although there are individual differences, the concentration of glucose contained in tears is about 0.001 to 0.01 w / v%. However, glucose is sometimes mixed as a nutrient in aqueous liquid preparations for ophthalmology at a higher concentration than tears. For example, the glucose concentration in the aqueous liquid preparations for ophthalmology disclosed in patent documents 1 to 4 is about 0.1 w / v%. On the other hand, among bacteria, there are bacteria that metabolize glucose to produce pyruvic acid to obtain energy, and glucose sometimes promotes the proliferation of such bacteria. Therefore, in particular, ophthalmic aqueous liquid preparations with reduced content of storage agents and preservatives are generally formulated with glucose at a lower concentration than that of tears.

[0003] Even if the concentration of glucose is reduced, a preservative is mixed in the pharmaceutical composition for the purpose of preservation. However, since eye drops are directly applied to the eyes, preservatives sometimes show side effects. For example, non-patent documents 1 to 5 state that preservatives such as benzalkonium chloride damage cells and cause irritation to the skin, and that povidone iodine has the lowest toxicity and alkyldiaminoethylglycine has a moderate toxicity. Patent documents 1 to 4 also disclose ophthalmic compositions containing alkyldiaminoethylglycine hydrochloride.

[0004] Prior art literature

[0005] Patent Literature

[0006] Patent Document 1: Japanese Patent Application Publication No. 2001-302518

[0007] Patent Document 2: Japanese Patent Application Publication No. 2001-302545

[0008] Patent Document 3: Japanese Patent Application Publication No. 2009-46480

[0009] Patent Document 4: Japanese Patent Application Publication No. 2005-336153

[0010] Non-patent literature

[0011] Non-patent document 1: Nobuo Takahashi et al., Japanese Ophthalmology, 58: 10, pp. 945-950 (1987)

[0012] Non-patent document 2: Akiyoshi Tsuji et al., Japanese Environmental Sensing, Vol. 11, No. 3, pp. 207-220 (1996)

[0013] Non-patent document 3: Toshiko, Vol.12, No.4, pp.67~73 (2003)

[0014] Non-patent document 4: Nakajima Keiji et al., Nikkei Yakushin, Vol. 40, No. 12, pp. 1559-1562 (2004)

[0015] Non-patent document 5: Shiraishi Masaru, Journal of the Japanese Society of Internal Medicine, Vol.99, No.8, pp.166-172 (2010) Summary of the invention

[0016] Problems to be solved by the invention

[0017] An object of the present invention is to provide a pharmaceutical composition for soft contact lenses which inhibits adsorption of alkyldiaminoethylglycine to soft contact lenses.

[0018] Methods for solving problems

[0019] The present inventors have conducted intensive studies to solve the above problems. As a result, they have found that if a low concentration of alkyldiaminoethylglycine hydrochloride is mixed in a pharmaceutical composition for soft contact lenses, alkyldiaminoethylglycine has a tendency to be adsorbed to soft contact lenses, but such adsorption can be suppressed by further mixing a metal chloride, thereby completing the present invention.

[0020] One aspect of the present invention is shown below.

[0021] [1] A pharmaceutical composition for soft contact lenses, comprising 0.001 w / v% to 0.008 w / v% of alkyldiaminoethylglycine hydrochloride and a metal chloride.

[0022] [2] The pharmaceutical composition for soft contact lenses according to [1] above, comprising 0.001 w / v% to 0.0075 w / v% of alkyldiaminoethylglycine hydrochloride.

[0023] [3] The pharmaceutical composition for soft contact lenses according to [1] above, comprising 0.001 w / v% to 0.005 w / v% of alkyldiaminoethylglycine hydrochloride.

[0024] [4] The pharmaceutical composition for soft contact lenses according to any one of [1] to [3] above, wherein the metal chloride is one or more salts selected from chlorides of alkali metals and chlorides of Group IIA metals.

[0025] [5] The pharmaceutical composition for soft contact lens according to any one of [1] to [3] above, wherein the metal chloride is sodium chloride and / or potassium chloride.

[0026] [6] The pharmaceutical composition for soft contact lens according to any one of [1] to [5] above, comprising 0.05 w / v% to 5.0 w / v% of the metal chloride.

[0027] [7] The pharmaceutical composition for soft contact lens according to any one of [1] to [5] above, comprising 0.1 w / v% to 2.0 w / v% of the metal chloride.

[0028] [8] The pharmaceutical composition for soft contact lens according to any one of [1] to [7] above, further comprising glucose.

[0029] [9] The pharmaceutical composition for soft contact lens according to [8] above, comprising 0.001 w / v% to 0.01 w / v% glucose.

[0030]

[10] The pharmaceutical composition for soft contact lens according to [8] above, comprising 0.002 w / v% to 0.008 w / v% glucose.

[0031]

[11] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[10] above, comprising 0.001 w / v% to 0.005 w / v% of alkyldiaminoethylglycine hydrochloride and 0.5 w / v% to 1 w / v% of a metal chloride.

[0032]

[12] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[11] above, comprising:

[0033] 0.001 w / v% or more and 0.005 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0034] 0.5 w / v% or more and 1 w / v% or less of a metal chloride, and

[0035] 0.002 w / v % or more and 0.008 w / v % or less of glucose.

[0036]

[13] The pharmaceutical composition for soft contact lens according to any one of [1] to

[12] above, further comprising a nonionic surfactant.

[0037]

[14] According to the pharmaceutical composition for soft contact lenses described in

[13] above, the nonionic surfactant is one or more nonionic surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan mono-long chain fatty acid esters, mono-long chain fatty acid polyethylene glycol esters, and polyoxyethylene polyoxypropylene block copolymers.

[0038]

[15] The pharmaceutical composition for soft contact lenses according to

[14] above, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil 60.

[0039]

[16] The pharmaceutical composition for soft contact lens according to any one of

[13] to

[15] above, wherein the concentration of the nonionic surfactant is 0.001 w / v% to 0.5 w / v%.

[0040]

[17] The pharmaceutical composition for soft contact lens according to any one of

[13] to

[15] above, wherein the concentration of the nonionic surfactant is 0.001 w / v % to 0.1 w / v %.

[0041]

[18] The pharmaceutical composition for soft contact lens according to any one of

[13] to

[15] above, wherein the concentration of the nonionic surfactant is 0.005 w / v% to 0.05 w / v%.

[0042]

[19] The pharmaceutical composition for soft contact lens according to any one of [1] to

[18] above, further comprising a buffer.

[0043]

[20] The pharmaceutical composition for soft contact lenses according to the above

[19] , wherein the buffer is one or more buffers selected from the group consisting of boric acid buffer, phosphate buffer, carbonate buffer, citric acid buffer, acetic acid buffer, HEPES buffer, and MOPS buffer.

[0044]

[21] The pharmaceutical composition for soft contact lenses according to the above

[19] , wherein the buffer is boric acid and / or borax.

[0045]

[22] The pharmaceutical composition for soft contact lens according to any one of

[19] to

[21] above, comprising 0.05 w / v% to 5.0 w / v% of a buffer.

[0046]

[23] The pharmaceutical composition for soft contact lens according to any one of

[19] to

[21] above, comprising 0.1 w / v% to 1.0 w / v% of a buffer.

[0047]

[24] The pharmaceutical composition for soft contact lens according to any one of [1] to

[23] above, further comprising a thickener.

[0048]

[25] The pharmaceutical composition for soft contact lenses according to

[24] above, wherein the thickener is hydroxypropylmethylcellulose.

[0049]

[26] The pharmaceutical composition for soft contact lens according to

[24] or

[25] above, comprising 0.01 w / v% to 1 w / v% of a thickener.

[0050]

[27] The pharmaceutical composition for soft contact lens according to

[24] or

[25] above, comprising 0.05 w / v% to 0.5 w / v% of a thickener.

[0051]

[28] The pharmaceutical composition for soft contact lens according to any one of [1] to

[27] above, further comprising an amino acid.

[0052]

[29] The pharmaceutical composition for soft contact lenses according to

[28] above, wherein the amino acid is one or more amino acids selected from taurine, glutamic acid, aspartic acid, glycine, alanine, arginine, lysine, γ-aminobutyric acid, γ-aminovaleric acid, and salts thereof.

[0053]

[30] The pharmaceutical composition for soft contact lenses according to

[28] above, wherein the amino acid is taurine.

[0054]

[31] The pharmaceutical composition for soft contact lens according to any one of

[28] to

[30] above, comprising 0.01 w / v% to 1.0 w / v% of an amino acid.

[0055]

[32] The pharmaceutical composition for soft contact lens according to any one of

[28] to

[30] above, comprising 0.05 w / v% to 0.5 w / v% of an amino acid.

[0056]

[33] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[31] above, comprising:

[0057] 0.001 w / v% or more and 0.005 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0058] 0.1w / v% or more and 2.0w / v% or less of metal chloride,

[0059] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0060] 0.005 w / v% or more and 0.05 w / v% or less of polyoxyethylene hydrogenated castor oil,

[0061] 0.1 w / v% or more and 2.0 w / v% or less of a buffer,

[0062] 0.05 w / v% or more and 0.5 w / v% or less of a thickener, and

[0063] 0.05 w / v% or more and 0.5 w / v% or less of amino acids.

[0064]

[34] The pharmaceutical composition for soft contact lens according to any one of [1] to

[33] above, further comprising a pH adjuster.

[0065]

[35] The pharmaceutical composition for soft contact lens according to any one of [1] to

[34] above, wherein the pH thereof is 5.0 to 8.5.

[0066]

[36] The pharmaceutical composition for soft contact lens according to any one of [1] to

[34] above, wherein the pH thereof is 5.5 or higher and 8.0 or lower.

[0067]

[37] The pharmaceutical composition for soft contact lens according to any one of [1] to

[34] above, wherein the pH thereof is 6.5 or higher and 7.5 or lower.

[0068]

[38] The pharmaceutical composition for soft contact lens according to any one of [1] to

[37] above, further comprising a monoterpene.

[0069]

[39] The pharmaceutical composition for soft contact lenses according to

[38] above, wherein the monoterpene is one or more monoterpenes selected from menthol, camphor, and borneol.

[0070]

[40] The pharmaceutical composition for soft contact lenses according to the above

[38] , wherein the monoterpene is l-menthol.

[0071]

[41] The pharmaceutical composition for soft contact lens according to any one of

[38] to

[40] above, comprising 0.0005 w / v% to 0.1 w / v% of monoterpene.

[0072]

[42] The pharmaceutical composition for soft contact lens according to any one of

[38] to

[40] above, comprising 0.001 w / v% to 0.035 w / v% of monoterpene.

[0073]

[43] The pharmaceutical composition for soft contact lens according to any one of [1] to

[42] above, further comprising a chelating agent.

[0074]

[44] The pharmaceutical composition for soft contact lenses according to

[43] above, wherein the chelating agent is ethylenediaminetetraacetic acid or a salt thereof.

[0075]

[45] The pharmaceutical composition for soft contact lens according to

[43] or

[44] above, which contains 0.001 w / v% to 0.1 w / v% of the chelating agent.

[0076]

[46] The pharmaceutical composition for soft contact lens according to

[43] or

[44] above, which contains 0.005 w / v% to 0.05 w / v% of a chelating agent.

[0077]

[47] The pharmaceutical composition for soft contact lens according to any one of [1] to

[46] above, comprising:

[0078] 0.001 w / v% or more and 0.005 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0079] 0.5 w / v% or more and 1.0 w / v% or less of metal chloride,

[0080] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0081] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0082] 0.1 w / v% or more and 2.0 w / v% or less of a buffer,

[0083] 0.05 w / v% or more and 0.5 w / v% or less of a thickener,

[0084] 0.05 w / v% or more and 0.5 w / v% or less of amino acids,

[0085] 0.001 w / v% or more and 0.035 w / v% or less of monoterpenes, and

[0086] 0.005 w / v% or more and 0.05 w / v% or less of the chelating agent.

[0087]

[48] ​​The pharmaceutical composition for soft contact lenses according to any one of [1] to

[46] above, comprising:

[0088] 0.001 w / v% or more and 0.005 w / v% or less of alkyldiaminoethylglycine hydrochloride,

[0089] 0.5 w / v% or more and 1.0 w / v% or less of metal chloride,

[0090] 0.002 w / v% or more and 0.008 w / v% or less of glucose,

[0091] 0.005 w / v% or more and 0.05 w / v% or less of a nonionic surfactant,

[0092] 0.1 w / v% or more and 2.0 w / v% or less of a buffer,

[0093] 0.05 w / v% or more and 0.5 w / v% or less of a thickener,

[0094] 0.05 w / v% or more and 0.5 w / v% or less of amino acids,

[0095] 0.001 w / v% or more and 0.035 w / v% or less of monoterpenes, and

[0096] 0.005 w / v% or more and 0.05 w / v% or less of a chelating agent,

[0097] The pH of the pharmaceutical composition for soft contact lenses is 6.5 or more and 7.5 or less.

[0098]

[49] The pharmaceutical composition for soft contact lens according to any one of [1] to

[48] above, which is used in ophthalmology.

[0099]

[50] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[48] above, which is an aqueous liquid preparation.

[0100]

[51] The pharmaceutical composition for soft contact lenses according to any one of [1] to

[48] above, which is an eye drop.

[0101]

[52] Use of a metal chloride for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens in a pharmaceutical composition comprising 0.001 w / v % to 0.008 w / v % of alkyldiaminoethylglycine hydrochloride.

[0102]

[53] Use of a metal chloride for producing a pharmaceutical composition for inhibiting adsorption of alkyldiaminoethylglycine to a soft contact lens in a pharmaceutical composition containing 0.001 w / v % or more and 0.008 w / v % or less of alkyldiaminoethylglycine hydrochloride.

[0103]

[54] A method for inhibiting the adsorption of alkyldiaminoethylglycine to soft contact lenses, characterized in that:

[0104] The content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses is 0.001 w / v% or more and 0.008 w / v% or less,

[0105] A metal chloride is blended into the pharmaceutical composition for soft contact lenses.

[0106]

[55] The method according to the above

[54] , wherein glucose is further mixed into the pharmaceutical composition for soft contact lenses.

[0107] The provisions of [1] to

[51] above can be applied to the above-mentioned uses and methods.

[0108] Effects of the Invention

[0109] The pharmaceutical composition for soft contact lenses according to the present invention contains alkyldiaminoethylglycine hydrochloride, but adsorption of alkyldiaminoethylglycine to soft contact lenses is suppressed. DETAILED DESCRIPTION

[0110] As described above, various pharmaceutical compositions have been developed, and preservatives are mixed in eye drops for the purpose of storage stability. Among the preservatives used in pharmaceutical compositions, alkyldiaminoethylglycine hydrochloride has a lower cytotoxicity than benzalkonium chloride and the like.

[0111] However, the present inventors have found that if alkyldiaminoethylglycine hydrochloride is mixed in a relatively low concentration in a pharmaceutical composition for soft contact lenses, alkyldiaminoethylglycine tends to be adsorbed to soft contact lenses. Therefore, the present inventors have studied components that inhibit such adsorption and have found that metal chlorides are effective.

[0112] The pharmaceutical composition for soft contact lenses according to the present invention contains 0.001 w / v% to 0.008 w / v% of alkyldiaminoethylglycine hydrochloride and a metal chloride.

[0113] Hereinafter, alkyldiaminoethylglycine may be abbreviated as "ADG", and soft contact lens may be abbreviated as "SCL".

[0114] "Alkyldiaminoethylglycine hydrochloride" is a compound having the following chemical structure, and has been used mainly as a preservative component in the past.

[0115] R-NH-(CH2)2-NH-(CH2)2-NH-CH2-CO2H·HCl

[0116] [wherein, R represents C8H 17 ~C 16 H 33 The alkyl groups are mainly C 12 H 25 and C 14 H 29 . ]

[0117] In order to provide a pharmaceutical composition for soft contact lenses with low cytotoxicity, the present inventors set the compounding amount of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lenses to be relatively low, 0.001w / v% or more and 0.008w / v% or less. If the concentration is 0.001w / v% or more, the antiseptic effect is more reliably exerted. On the other hand, if the concentration is 0.008w / v% or less, the cytotoxicity is more reliably suppressed. In addition, the present inventors have found through experiments that the lower the concentration of alkyldiaminoethylglycine hydrochloride, the higher the adsorption rate of alkyldiaminoethylglycine on soft contact lenses. As the concentration, it is preferably 0.002w / v% or more, and it is preferably 0.005w / v% or less, and more preferably 0.003w / v% or less.

[0118] The so-called "metal chloride" refers to the metal cation and chloride ion (Cl - ) is mixed as a component that hinders the adsorption of alkyldiaminoethylglycine to soft contact lenses in the present invention. Examples of metal chlorides include alkali metal chlorides such as sodium chloride and potassium chloride; Group IIA metal chlorides such as calcium chloride and magnesium chloride, preferably alkaline earth metal chlorides such as calcium chloride, and preferably water-soluble metal chlorides. The so-called "soluble in water" means that after the test object is made into a fine powder that can pass through a No. 100 (mesh size: 150 μm) sieve, 1 g is added to water, and when it is vigorously shaken for 30 seconds every 5 minutes at 20°C, the amount of water required to dissolve it within 30 minutes is less than 10 mL.

[0119] The concentration of the metal chloride in the pharmaceutical composition for soft contact lenses may be appropriately adjusted within the range in which the above-mentioned adsorption effect is effectively exerted, and may be, for example, 0.05 w / v% or more and 5.0 w / v% or less. If the concentration is within this range, the above-mentioned adsorption effect is exerted more reliably. The concentration is preferably 0.1 w / v% or more, more preferably 0.5 w / v% or more, and preferably 2.0 w / v% or less, more preferably 1.0 w / v% or less.

[0120] The metal chloride may be used alone or in combination of two or more. When two or more metal chlorides are used, the above concentration is a total concentration.

[0121] Glucose has the formula C6H 12 One of the aldohexoses represented by O6, also called glucose, exists in nature as D-glucose, and in animals with a respiratory system, it conjugates with the electron transport system to generate a large amount of ATP, and exists in tears at a concentration of more than 0.001 w / v% and less than 0.01 w / v%.

[0122] In the present invention, in order to assist the adsorption inhibition effect of alkyldiaminoethylglycine on soft contact lenses brought about by metal chlorides, it is preferred to mix glucose. It is preferred that 0.001 w / v% or more and 0.01 w / v% or less of glucose is mixed in the pharmaceutical composition for soft contact lenses according to the present invention. If the ratio is 0.001 w / v% or more, the above-mentioned adsorption inhibition effect brought about by metal chlorides can be more reliably protected, and if the ratio is 0.01 w / v% or less, the stability of the eye drops can be more reliably ensured. As this ratio, it is more preferably 0.002 w / v% or more, and more preferably 0.004 w / v% or more, and more preferably 0.008 w / v% or less, and more preferably 0.006 w / v% or less.

[0123] "Nonionic surfactants" are surfactants that do not dissociate into ions even when dissolved in water. Generally, polyoxyethylene chains and hydroxyl groups act as hydrophilic groups, and long-chain alkyl groups become hydrophobic groups. Nonionic surfactants contribute to the stability of eye drops. Examples of nonionic surfactants include one or more nonionic surfactants selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan mono-long chain fatty acid esters, mono-long chain fatty acid polyethylene glycol esters, and polyoxyethylene polyoxypropylene block copolymers.

[0124] The so-called polyoxyethylene hydrogenated castor oil is a compound obtained by etherifying hydrogenated castor oil with a polyoxyethylene chain. The number of moles of ethylene oxide added to the polyoxyethylene chain in the polyoxyethylene hydrogenated castor oil can be, for example, 5 or more and 100 or less. As this number, it is preferably 10 or more or 20 or more, more preferably 30 or more, and further preferably 40 or more. In addition, it is preferably 90 or less, more preferably 80 or less, and further preferably 70 or less. As the polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 5, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 60, etc. can be used, and polyoxyethylene hydrogenated castor oil 60 can be used appropriately. In addition, the number after the polyoxyethylene hydrogenated castor oil represents the number of moles of ethylene oxide added.

[0125] Polyoxyethylene sorbitan mono-long chain fatty acid ester is also called polysorbate. It is a polyoxyethylene ether of sorbitan fatty acid ester obtained by heating sorbitol and long-chain fatty acid under an alkali catalyst to generate sorbitan long-chain fatty acid ester, and condensing ethylene oxide with the sorbitan long-chain fatty acid ester. Usually, a total of 18 or more molecules and 22 or less molecules of ethylene oxide are bound to each molecule. The number of carbon atoms of long-chain fatty acids is generally 10 or more and 20 or less. As long-chain fatty acids, for example, lauric acid, palmitic acid, stearic acid, oleic acid, etc. can be cited. As polyoxyethylene sorbitan mono-long chain fatty acid ester, for example, polysorbate 20, polysorbate 60, polysorbate 65, polysorbate 80 can be used, preferably polysorbate 80.

[0126] The mono-long-chain fatty acid polyethylene glycol ester is an ester of a long-chain fatty acid and polyethylene glycol, and examples of the long-chain fatty acid include stearic acid, and the degree of polymerization of the polyethylene glycol is about 10 to 60. The mono-long-chain fatty acid polyethylene glycol ester is preferably polyoxyl 40 stearate.

[0127] The polyoxyethylene polyoxypropylene block copolymer is a copolymer of propylene oxide and ethylene oxide. Examples of the polyoxyethylene polyoxypropylene block copolymer include polyoxyethylene (160) polyoxypropylene (30) diol (Poloxamer 188), polyoxyethylene (196) polyoxypropylene (67) diol (Poloxamer 407), and poloxamer 235.

[0128] The concentration of the nonionic surfactant in the pharmaceutical composition can be adjusted appropriately, for example, 0.001 w / v% or more and 0.5 w / v% or less. If the concentration is within this range, the stabilizing effect of the pharmaceutical composition can be more effectively exerted. As the concentration, it is preferably 0.005 w / v% or more, more preferably 0.008 w / v% or more, and in addition, it is preferably 0.1 w / v% or less, more preferably 0.05 w / v% or less, and further preferably 0.02 w / v% or less.

[0129] The so-called "buffer" refers to a compound mainly used to moderate the change of pH caused by external substances, and for example, one or more buffers selected from boric acid buffer, phosphate buffer, carbonate buffer, citric acid buffer, acetic acid buffer, HEPES buffer, and MOPS buffer can be cited. As the buffer, a boric acid buffer is preferred, and boric acid and / or borax are more preferred. Boric acid and borax can also be used as preservatives and also show disinfection effects on the conjunctival sac.

[0130] The concentration of the buffer in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, 0.05 w / v% or more and 5.0 w / v% or less. If the concentration is within this range, the buffering effect brought about by the buffer is more reliably exerted. As the concentration, it is preferably 0.1 w / v% or more, more preferably 0.5 w / v% or more, and preferably 2.0 w / v% or less, more preferably 1.0 w / v% or less.

[0131] The so-called "thickener" is a component that increases the viscosity of the pharmaceutical composition for soft contact lenses and contributes to the suppression of rapid evaporation of the pharmaceutical composition for soft contact lenses, the improvement of liquid shearing properties, the suppression of variation in the amount of drop added, the improvement of the feeling of use, etc. Glucose is also compounded as an isotonicity agent and a thickener in the pharmaceutical composition, but in the present invention, glucose is compounded as a component for assisting the effect of suppressing the adsorption of alkyldiaminoethylglycine to soft contact lenses by metal chlorides, and therefore, for convenience, glucose is excluded from the category of thickeners in the present invention.

[0132] The viscosity of the pharmaceutical composition for soft contact lenses of the present invention can be appropriately adjusted, for example, 1.0 mPa·s to 200 mPa·s. The viscosity is preferably 50 mPa·s or less or 30 mPa·s or less, more preferably 10 mPa·s or less, and even more preferably 3.0 mPa·s or less.

[0133] Examples of the thickener include hydroxypropylmethylcellulose, carboxyvinyl polymer, hydroxyethylcellulose, methylcellulose, alginic acid, polyvinyl alcohol, and polyvinyl pyrrolidone, and hydroxypropylmethylcellulose is preferred.

[0134] The concentration of the thickener in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, from 0.01 w / v% to 1.0 w / v%. If the concentration is within this range, the above-mentioned effect brought about by the thickener is more surely exerted. As the concentration, it is preferably from 0.05 w / v% to 0.08 w / v%, more preferably from 0.5 w / v% to 0.2 w / v%.

[0135] The so-called "amino acid" is a compound having an acidic group such as a carboxyl group, a sulfonic acid group (-SO3H) and an amino group in one molecule, and is not limited to the 20 so-called protein-constituting amino acids. Amino acids are mainly nutrients for the eyes and help to reduce eye fatigue. As amino acids, for example, one or more amino acids selected from taurine, glutamic acid, aspartic acid, glycine, alanine, arginine, lysine, γ-aminobutyric acid, γ-aminovaleric acid, and their salts can be cited. As amino acid salts, alkali metal salts such as sodium salts and potassium salts can be cited. As an amino acid, taurine is preferred. In addition to being a nutrient, taurine is generally believed to also show a metabolic promoting effect.

[0136] The concentration of the amino acid in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, 0.01 w / v% or more and 1.0 w / v% or less. If the concentration is within this range, the effect of each amino acid is more reliably exerted. As the concentration, it is preferably 0.05 w / v% or more, more preferably 0.08 w / v% or more, and further preferably 0.1 w / v% or more, and preferably 0.5 w / v% or less, and more preferably 0.2 w / v% or less.

[0137] The pH of the pharmaceutical composition for soft contact lenses of the present invention is adjusted to a range that can be applied to a living body, particularly an eye. The pH may be, for example, 5.0 or more and 8.5 or less, preferably 5.5 or more, more preferably 6.0 or more, and even more preferably 6.5 or more, and preferably 8.0 or less, and more preferably 7.5 or less. In the present invention, it has been experimentally demonstrated that the adsorption inhibitory effect of alkyldiaminoethylglycine on soft contact lenses brought about by metal chloride is particularly significantly exerted in the pH range of 6.5 or more and 7.5 or less. The pH of the pharmaceutical composition for soft contact lenses may be adjusted by the above-mentioned buffer or by a pH adjuster.

[0138] There are no particular restrictions on the pH adjuster as long as it can be applied to a living body, especially the eye, and examples thereof include inorganic acids such as hydrochloric acid and boric acid; organic acids such as acetic acid, glutamic acid, and aspartic acid; inorganic bases such as sodium hydroxide, sodium carbonate, and sodium bicarbonate; and organic bases such as triethanolamine and monoethanolamine. The type and amount of the pH adjuster may be determined according to the pH to be adjusted in the pharmaceutical composition for soft contact lenses.

[0139] "Monoterpenes" are composed of two isoprene units and have C 10 H 16In the present invention, monocyclic monoterpenes showing a cooling effect are mainly used. As monoterpenes, for example, one or more monoterpenes selected from menthol, camphor, and borneol can be mentioned. As menthol, both l-menthol and dl-menthol can be used, but l-menthol is preferred. Both d-form and dl-form of camphor and borneol can be used, but d-form is preferred.

[0140] The concentration of the monoterpene in the pharmaceutical composition for soft contact lenses can be appropriately adjusted, and can be, for example, 0.0005 w / v% or more and 0.1 w / v% or less. If the concentration is within this range, a moderate cooling sensation can be obtained more reliably. The concentration is preferably 0.001 w / v% or more, more preferably 0.0015 w / v% or more, and preferably 0.02 w / v% or less, more preferably 0.01 w / v% or less.

[0141] "Chelating agents" improve the stability of eye drops by blocking metal ions such as calcium ions and inhibiting the formation of insoluble metal salts. As chelating agents, there are no particular restrictions as long as they can be applied to organisms, especially eyes, and have such effects. For example, ethylenediaminetetraacetic acid (EDTA), ascorbic acid, citric acid, and salts thereof can be cited. As salts of EDTA, for example, tetrasodium EDTA and disodium EDTA can be cited.

[0142] The concentration of the chelating agent in the pharmaceutical composition for soft contact lenses can be adjusted appropriately, for example, from 0.001 w / v% to 0.2 w / v%. If the concentration is within this range, the stabilization effect brought about by the chelating agent can be more reliably obtained. The concentration is preferably from 0.002 w / v% to 0.005 w / v%, more preferably from 0.2 w / v%, more preferably from 0.05 w / v%, and even more preferably from 0.02 w / v%.

[0143] In the pharmaceutical composition for soft contact lenses to which the present invention relates, there is no particular limitation within the scope of not damaging the effect of the present invention, but a storage agent or preservative other than alkyl diaminoethyl glycine hydrochloride may be added. As storage agents or preservatives, for example, benzalkonium chloride, benzalkonium bromide, benzethonium chloride, chlorhexidine hydrochloride, chlorhexidine gluconate, chlorhexidine acetate, chlorobutanol, benzyl alcohol, phenethyl alcohol, sorbic acid or its salt, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, dehydroacetic acid or its salt, zinc chloride, polychloride, sodium thiomercurate, butylated hydroxytoluene, sodium chlorite, boric acid, borax, etc. may be enumerated. These storage agents or preservatives may be used alone or in combination of two or more.

[0144] In addition, each of the above components may be used alone or in combination of two or more as appropriate.

[0145] Soft contact lenses are classified into four types by the FDA (Food and Drug Administration). That is, they are classified into Group I: non-ionic soft contact lenses with a water content of less than 50%, Group II: non-ionic soft contact lenses with a water content of 50% or more, Group III: ionic soft contact lenses with a water content of less than 50%, and Group IV: ionic soft contact lenses with a water content of 50% or more. Soft contact lenses with a molar percentage of anionic monomers among the constituent monomers of the raw material polymer of 1% or more are ionic, and soft contact lenses with a molar percentage of less than 1% are non-ionic. The soft contact lenses in the present disclosure may be any of the above-mentioned soft contact lenses, regardless of the difference between ionic or non-ionic, hydrated or non-hydrated.

[0146] In addition, in the present disclosure, “soft contact lenses” include, for example, soft contact lenses with 2-hydroxyethyl methacrylate (HEMA), EGDMA, SiMAA2, mPDMS1000, CE-PDMS, TRIS, EMA, methacryloyloxyethyl phosphorylcholine, TrisVC, MMA, MA, polyethylene glycol monomethacrylate (PEGMA), glyceryl methacrylate (GMA), N,N-dimethylacrylamide (DMA), vinyl alcohol (VA), N-vinyl pyrrolidone (NVP or VP), methacrylic acid (MAA), fluorine-containing methacrylate compounds, silicon-containing methacrylate compounds, silicone hydrogels, cycloalkyl methacrylates, etc. as main components.

[0147] The soft contact lens in the present disclosure may be any of the above materials, but preferably a soft contact lens having 2-hydroxyethyl methacrylate (HEMA) as the main component can be mentioned, and more preferably a soft contact lens having 2-hydroxyethyl methacrylate (HEMA) and EGDMA as the main components, or a soft contact lens having HEMA and methacryloyloxyethyl phosphorylcholine as the main components can be mentioned.

[0148] The type of soft contact lenses is not particularly limited, and disposable soft contact lenses, periodic replacement soft contact lenses, existing soft contact lenses, silicone hydrogel contact lenses, and colored contact lenses can all be used.

[0149] Silicone hydrogel contact lenses are contact lenses made of silicone hydrogel.

[0150] Colored contact lenses, also called tinted contact lenses, are contact lenses that are colored for the purpose of eye decoration, beauty, etc. For example, colored contact lenses make the iris and cornea color area appear larger than when the contact lenses are not worn. More specifically, they are used to color an area larger than the periphery of the iris and cornea. Sometimes, such colored contact lenses are also called circle lenses.

[0151] As the pigment used for coloring the colored contact lenses, known pigments such as inorganic pigments and organic pigments can be used. Examples of such pigments include azo pigments, phthalocyanine pigments, diketopyrrolopyrrole pigments, anthraquinone pigments, and tribenzophenone pigments. Alkane pigment, violet anthrone pigment, isoindoline pigment, carbazole pigment, quinoline pigment, metal oxide pigment, carbon black etc., according to the color, design etc. of colored contact lens, can be used in combination of one or more than two kinds. In the present disclosure, even if it is called the material of pigment, dye, also can be used by known means. In addition, no matter it is the soft contact lens that is not a colored soft contact lens, or transparent contact lens, sometimes when being immersed in the solution such as cleaning solution, it is colored as light color to the degree that can be easily visually distinguished.

[0152] The pharmaceutical composition for soft contact lenses of the present invention can be prepared by conventional methods. For example, each component can be dissolved in water as a solvent. The water used as the solvent is, for example, distilled water, purified water, sterilized water, etc., clear water in which impurities, bacteria, viruses, fungi, etc. are less than the detection limit or sufficiently small.

[0153] The container of holding the pharmaceutical composition for soft contact lens of the present invention is not particularly limited, as long as it is the container used as eye drop container in the past, can be glass system, in addition can also be plastic system.As the container of holding the pharmaceutical composition for soft contact lens of the present invention, when using plastic system, the constituent material of this plastic container is not particularly limited, for example, can enumerate any one or two or more mixtures in polyethylene naphthalate, polyarylate, polyethylene terephthalate, polybutylene terephthalate, polypropylene, polyethylene, polyimide.Consider from the viewpoint of more surely guaranteeing the stability of the pharmaceutical composition for soft contact lens, as the material of the member of the housing portion that forms the container body, namely holds the pharmaceutical composition for soft contact lens, preferably polyethylene terephthalate, polypropylene or polyethylene, more preferably polyethylene terephthalate.

[0154] The inhibition of adsorption of alkyldiaminoethylglycine to soft contact lenses in the pharmaceutical composition for soft contact lenses of the present invention is evaluated by the following method: the adsorption rate of alkyldiaminoethylglycine contained in the pharmaceutical composition for soft contact lenses after the soft contact lenses are immersed is lower than the adsorption rate of alkyldiaminoethylglycine to the soft contact lenses after the soft contact lenses are immersed in a liquid of the same composition except that the metal chloride is not contained. The immersion of the soft contact lenses can be performed, for example, by shaking the liquid in which the soft contact lenses are immersed at 25° C. for 24 hours. The amount of alkyldiaminoethylglycine can be measured, for example, by the absorbance of light of a wavelength of a liquid obtained by reacting a coloring agent such as Eosin Y with alkyldiaminoethylglycine, high performance liquid chromatography, etc.

[0155] The pharmaceutical composition for soft contact lenses according to the present invention assists tear production and is effective in alleviating discomfort, dry eyes, eye fatigue, blurred vision, etc. when wearing soft contact lenses.

[0156] The pharmaceutical composition of the present invention can be used in any form of oral administration or external use according to the purpose. As an oral form, it can be used for internal medicine, etc., and as an external form, it can be provided as a local liquid preparation for various uses such as ophthalmology, dentistry, otolaryngology, dermatology, etc. It is particularly preferably used for ophthalmology.

[0157] The so-called "ophthalmic pharmaceutical composition" refers to a pharmaceutical composition for ophthalmic use. As the pharmaceutical composition, in particular, an aqueous liquid preparation containing water as a solvent can be mentioned. The so-called "aqueous liquid preparation" refers to a liquid pharmaceutical composition containing water as a solvent. The aqueous liquid preparation can be prepared by a conventional method such as dissolving or dispersing each component in water as a solvent, and can be a solution, a suspension, or an emulsion, but is preferably an aqueous liquid preparation as a solution.

[0158] Examples of ophthalmic pharmaceutical compositions include eye drops (including eye drops that can be used while wearing soft contact lenses, also referred to as eye drops or eye drops), eye washes (including eye washes that can be used while wearing soft contact lenses, also referred to as eye wash solutions or eye wash medicines), eye ointments, soft contact lens wearing solutions, soft contact lens care agents (cleaning solutions, storage solutions, bactericidal solutions, disinfecting solutions {including multi-purpose care solutions}, etc.), preferably eye drops, contact lens wearing solutions, eye washes or soft contact lens care agents, and particularly preferably eye drops.

[0159] The pharmaceutical composition of the present invention includes eye drops that can be used while wearing soft contact lenses. That is, the pharmaceutical composition of the present invention can be applied to eyes while wearing soft contact lenses. The types of soft contact lenses are not particularly limited, and disposable soft contact lenses, regularly replaced soft contact lenses, existing soft contact lenses, silicone hydrogel contact lenses, and colored contact lenses can all be used. Silicone hydrogel contact lenses are contact lenses made of silicone hydrogel.

[0160] The usage and dosage of the eye drops of the present invention vary depending on the symptoms, age, etc. of the patient, but usually, the eye drops are instilled once or more and six times or less per day, with 1 drop or more and 3 drops or less each time.

[0161] The container used for the pharmaceutical composition of the present invention is sterilized according to conventional methods. The sterilization method is not particularly limited as long as it is a commonly used method, and examples thereof include dry heat sterilization, electron beam sterilization, gamma ray sterilization, ethylene gas sterilization, etc. In one embodiment, the sterilization treatment is electron beam sterilization.

[0162] The present invention also relates to a method for inhibiting adsorption of alkyldiaminoethylglycine to soft contact lenses, characterized in that the content of alkyldiaminoethylglycine hydrochloride in a pharmaceutical composition for soft contact lenses is 0.001 w / v% or more and 0.008 w / v% or less, and a metal chloride is mixed in the pharmaceutical composition for soft contact lenses. In this method, adsorption of alkyldiaminoethylglycine to soft contact lenses is further effectively inhibited by mixing glucose in addition to alkyldiaminoethylglycine hydrochloride and the metal chloride in the pharmaceutical composition for soft contact lenses.

[0163] In the above-mentioned adsorption inhibition method, the content of alkyldiaminoethylglycine hydrochloride in the pharmaceutical composition for soft contact lens is limited to 0.001 w / v% or more and 0.008 w / v% or less because the adsorption rate of alkyldiaminoethylglycine to soft contact lens increases in such a low concentration range.

[0164] In the above-mentioned adsorption inhibition method, the types and concentrations of the alkyldiaminoethylglycine hydrochloride, metal chloride, glucose, and other optional components used may be those related to the above-mentioned pharmaceutical composition for soft contact lenses, either alone or in combination. The same also applies to the pH, container, etc. of the pharmaceutical composition for soft contact lenses.

[0165] This application claims the benefit of priority based on Japanese Patent Application No. 2019-217422 filed on November 29, 2019. The entire contents of the specification of Japanese Patent Application No. 2019-217422 filed on November 29, 2019 are incorporated herein by reference.

[0166] Example

[0167] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples and can be implemented with appropriate modifications within the scope suitable for the aforementioned / later described purpose, and all of them are included in the technical scope of the present invention.

[0168] Test Example 1: Adsorption test on soft contact lenses

[0169] The quantitative alkyl diaminoethyl glycine hydrochloride solution ("Lebon LAG-40" manufactured by Sanyo Chemical Industries, Ltd.) was diluted with purified water, boric acid (manufactured by Borax Francais Co., Ltd.) and borax (manufactured by Kosakai Pharmaceutical Co., Ltd.) were added, and the pH was adjusted to 7 using hydrochloric acid to prepare a solution of the composition shown in Table 1. In addition, the values ​​in the table are w / v%. The soft contact lenses belonging to Group I ("Shedo 1day Fine UV plus" manufactured by Shedo Co., Ltd.) were washed with purified water. The above aqueous solution (3 mL) was measured into a vial, and one soft contact lens washed with purified water was immersed in it, and it was shaken at 25°C for 24 hours to be set as the SCL immersion solution. In addition, for another aqueous solution that was not immersed in soft contact lenses, it was also shaken at 25°C for 24 hours to be set as the control test solution. The above tests were implemented in 2 cases each. In the table, "ADG" represents alkyl diaminoethyl glycine.

[0170] Separately, accurately weigh the alkyl diaminoethyl glycine hydrochloride solution (62.5 mg) for quantitative determination, add water to make the total volume accurately 100 mL. Accurately weigh this liquid (2 mL), add water to make the total volume accurately 20 mL, and set it as the standard solution. Accurately weigh the SCL immersion solution and the standard solution (50 μL), and calculate the sum of the peak areas of alkyl diaminoethyl glycine by liquid chromatography under the following conditions.

[0171] Column: 4.6 mm inner diameter x 15 cm length cyanopropyl silylated silica gel ("CN12S05-1546WT" manufactured by Wiemshi Co., Ltd.)

[0172] Detector: UV absorbance photometer

[0173] Measurement wavelength: 210nm

[0174] Mobile phase: water / methanol / phosphoric acid mixture for liquid chromatography (750 / 250 / 1)

[0175] The ADG content in the SCL immersion solution was determined from the measured ADG peak area and the following formula, and the adsorption rate of ADG to the soft contact lens was further calculated.

[0176] ADG hydrochloride content in SCL immersion solution or control test solution (μg / mL) = weighed amount of ADG hydrochloride solution for quantification (mg) × content of ADG hydrochloride solution for quantification (w / v%) / 100 / 1.03 / S s ×S T

[0177] [Wherein, 1.03 represents the density of the ADG hydrochloride solution used for quantification (g / cm 3 ), S s represents the ADG peak area and S of the standard solution T It represents the sum of the ADG peak areas in the SCL immersion solution or the control test solution.]

[0178] In addition, the adsorption rate of ADG to the soft contact lens was calculated from the following formula.

[0179] Adsorption rate of ADG hydrochloride (%) = 100-[(C TAV / C CAV )×100]

[0180] [Wherein, C TAV represents the average content of ADG in the SCL immersion solution (μg / mL), C CAV It indicates the average content of ADG in the control test solution (μg / mL).

[0181] [Table 1]

[0182]

[0183] As shown in the results of Table 1, it was confirmed that the lower the ADG concentration, the higher the ratio of ADG adsorbed to the soft contact lens.

[0184] Test Example 2: Research on raw materials for soft contact lenses

[0185] Reference Example 2 of Test Example 1 was set as Comparative Example 1, and a preparation in which 0.55 w / v% of sodium chloride (manufactured by Manack) was mixed in Reference Example 2 was set as Example 1. Under the same conditions as in Test Example 1, SCL immersion solutions and control test solutions of soft contact lenses of Groups I to IV shown in Table 2 were obtained. The test was performed on 3 cases each. Groups I to IV are classifications of the FDA (U.S. Food and Drug Administration), Group I is a nonionic lens with a water content of less than 50%, Group II is a nonionic lens with a water content of 50% or more, Group III is an ionic lens with a water content of less than 50%, and Group IV is an ionic lens with a water content of 50% or more.

[0186] Separately accurately weigh the quantitative alkyl diaminoethyl glycine hydrochloride solution ("Lebon LAG-40" manufactured by Sanyo Chemical Industries, Ltd.) (62.5 mg), add water to make the total volume exactly 100 mL. Add the added solution (25 mL) in which boric acid (manufactured by Borax Francais) (0.5 g) and borax (manufactured by Kosakai Pharmaceutical Co., Ltd.) (40 mg) are dissolved in water to make the total volume 50 mL to the liquid (5 mL), and further add water to make the total volume exactly 50 mL, which is set as the standard solution. In addition, water is added to the added solution (10 mL) to make the total volume exactly 20 mL, which is set as the control solution.

[0187] In the SCL immersion liquid, the control test liquid, the standard solution and the control solution (2 mL), potassium dihydrogen phosphate (manufactured by Fujifilm Wako Pure Pharmaceutical Co., Ltd.) (3.4 g) and eosin Y (manufactured by Fujifilm Wako Pure Pharmaceutical Co., Ltd.) (24 mg) were dissolved in water to adjust the total volume to 100 mL of eosin solution (4 mL) and stirred. For these liquids, the absorbance at a wavelength of 545 nm was measured, and the amount of ADG contained in the SCL immersion liquid and the control test liquid was calculated by the following formula, and the adsorption rate was further calculated in the same manner as in Reference Example 1. In addition, the adsorption inhibition rate was also calculated. The results are shown in Table 2. In Table 2, "SHCL" represents a silicone hydrogel contact lens containing silicon. When "Wand Acoustic Monitor" (manufactured by Dionson Endo Co., Ltd.) of Group IV was used, SCL was deformed, but the measurement was performed in the same manner as the others.

[0188] The amount of ADG hydrochloride in the SCL immersion solution and the control test solution (w / v%) = the amount of ADG hydrochloride solution weighed for quantification (mg) / 1.03×M / 100×(A T -A C ) / (A S -A C )

[0189] [Wherein, 1.03 represents the density of the ADG hydrochloride solution used for quantification (g / cm3 ), M represents the concentration of ADG hydrochloride for quantification (w / v%), A T Indicates the absorbance of SCL immersion solution or control test solution, A C represents the absorbance of the control solution, A S Indicates the absorbance of the standard solution.]

[0190] Adsorption inhibition rate (%) = [(ADG adsorption rate (%) of Comparative Example 1 - ADG adsorption rate (%) of Example 1) / ADG adsorption rate (%) of Comparative Example 1] × 100

[0191] [Table 2]

[0192]

[0193] As shown in the results in Table 2, when a soft contact lens is immersed in an alkyldiaminoethylglycine hydrochloride solution having a low concentration of 0.0025 w / v%, it is confirmed that alkyldiaminoethylglycine tends to be adsorbed to the soft contact lens.

[0194] However, it was found that when sodium chloride was added in addition to low concentration of alkyldiaminoethylglycine hydrochloride, the adsorption of alkyldiaminoethylglycine was uniformly suppressed. Such adsorption suppression effect was found to be particularly high when hydroxyethyl methacrylate (HEMA) was included in the raw material of the soft contact lens.

[0195] Test Example 3: Effect of adding glucose

[0196] Under the same conditions as in Test Example 1, a preparation (Comparative Example 1) in which boric acid and borax were mixed in addition to alkyldiaminoethylglycine hydrochloride, and a preparation (Examples 1 to 3) of the composition shown in Table 3 in which sodium chloride or sodium chloride and glucose (manufactured by San Ei Glycine) were further mixed were used to determine the adsorption rate of alkyldiaminoethylglycine on soft contact lenses and the adsorption inhibition rate relative to the preparation of Comparative Example 1. This test used "Shedo 1day Fine UV plus" manufactured by Shedo as a soft contact lens, and two examples of each were implemented. The results are shown in Table 3.

[0197] [Table 3]

[0198]

[0199] As shown in the results in Table 3, it was found that the adsorption of alkyldiaminoethylglycine was inhibited by sodium chloride, and that the adsorption inhibition effect was enhanced by the combined use of glucose.

[0200] Furthermore, it was confirmed that the above-mentioned effect of glucose was particularly high when it was mixed at a relatively low concentration.

[0201] Test Example 4: Effect of adding metal chlorides other than sodium chloride

[0202] Under the same conditions as in Test Example 2, the adsorption rate of alkyldiaminoethylglycine on soft contact lenses and the adsorption inhibition rate of the preparation of Comparative Example 1 containing only alkyldiaminoethylglycine were determined using the preparations of the composition shown in Table 4 mixed with sodium chloride or potassium chloride (manufactured by Ako Chemicals Co., Ltd.) or calcium chloride (manufactured by Tomita Pharmaceutical Co., Ltd.) instead of sodium chloride. The test was carried out for 2 cases each using "シード 1dayFine UV plus" manufactured by シード Corporation as soft contact lenses. The results are shown in Table 4.

[0203] [Table 4]

[0204]

[0205] As shown in the results in Table 4, it was found that the adsorption of alkyldiaminoethylglycine to soft contact lenses was suppressed not only by sodium chloride but also by other metal chlorides such as potassium chloride and calcium chloride.

[0206] Test Example 5: Study on Sodium Chloride Concentration

[0207] Under the same conditions as in Test Example 2, the adsorption rate of alkyldiaminoethylglycine on soft contact lenses and the adsorption inhibition rate of the preparation of Comparative Example 1 containing only alkyldiaminoethylglycine were determined using the preparation of the composition shown in Table 5 with the sodium chloride concentration changed. The test used "シード1dayFine UVplus" manufactured by シード Corporation as soft contact lenses, and two examples were implemented. The results are shown in Table 5.

[0208] [Table 5]

[0209]

[0210] As shown in the results of Table 5, the adsorption of alkyldiaminoethylglycine to soft contact lenses was inhibited by 0.1 to 0.8 w / v % of sodium chloride. Although the adsorption inhibition effect was slightly reduced at 0.1 w / v %, the adsorption inhibition effect was almost the same within the range of 0.3 to 0.8 w / v %.

[0211] Test Example 6: Study on the concentration of alkyl diaminoethyl glycine hydrochloride

[0212] Under the same conditions as in Test Example 1, the adsorption rate of alkyldiaminoethylglycine on soft contact lenses and the adsorption inhibition rate relative to a preparation containing alkyldiaminoethylglycine at the same concentration and not containing sodium chloride were determined using the preparation of the composition shown in Table 6 in which the concentration of alkyldiaminoethylglycine hydrochloride was changed. This test used "シード1dayFine UV plus" manufactured by シード Corporation as a soft contact lens, and three cases were carried out for each. The results are shown in Table 6.

[0213] [Table 6]

[0214]

[0215] As shown in the results of Table 6, it can be seen that the adsorption of alkyldiaminoethylglycine to soft contact lenses is more effectively suppressed by sodium chloride as the concentration of alkyldiaminoethylglycine hydrochloride is lower, and is particularly effectively suppressed when the concentration of alkyldiaminoethylglycine hydrochloride is 0.005 w / v% or less.

[0216] Test Example 7: Confirmation of the effect on colored soft contact lenses

[0217] Under the same conditions as in Test Example 1, using the formulations of the composition shown in Table 7, the adsorption rate of alkyldiaminoethylglycine on "Wanderly Fine UV Plus" manufactured by Froomeyes and "Tronpuruiyu Vande" manufactured by Vibrationia, which are colored soft contact lenses made of the same raw materials as "Sider 1day Fine UV plus" manufactured by Sider, and the adsorption inhibition rate relative to a formulation (Comparative Example 4) containing no sodium chloride and the same concentration of alkyldiaminoethylglycine were determined. The test was performed for 3 cases each. The results are shown in Table 7.

[0218] [Table 7]

[0219]

[0220] As shown in the results of Table 7, it was found that the effect of suppressing the adsorption of alkyldiaminoethylglycine to soft contact lenses by sodium chloride is also exerted on colored soft contact lenses (colored contact lenses).

[0221] Test Example 8: pH Study

[0222] Under the same conditions as in Test Example 1, the adsorption rate of alkyldiaminoethylglycine on soft contact lenses and the adsorption inhibition rate relative to a preparation containing alkyldiaminoethylglycine at the same concentration and not containing sodium chloride were determined using a preparation of the composition shown in Table 8 whose pH was adjusted by hydrochloric acid or sodium hydroxide aqueous solution. This test used "シード1dayFine UV plus" manufactured by シード Corporation as a soft contact lens, and three cases were carried out for each. The results are shown in Table 8.

[0223] [Table 8]

[0224]

[0225] As shown in the results of Table 8, it was found that the effect of inhibiting the adsorption of alkyldiaminoethylglycine to soft contact lenses by sodium chloride was particularly significantly exerted in the pH range of 6.5 to 7.5.

Claims

1. A pharmaceutical composition for soft contact lenses, comprising 0.001 w / v% to 0.008 w / v% of alkyldiaminoethylglycine hydrochloride, 0.3 w / v% to 0.8 w / v% of a metal chloride, and 0.001 w / v% to 0.01 w / v% of glucose, wherein the metal chloride is at least one selected from sodium chloride, potassium chloride and calcium chloride.

2. A pharmaceutical composition for soft contact lenses, comprising 0.001 w / v% to 0.003 w / v% of alkyldiaminoethylglycine hydrochloride, 0.3 w / v% to 0.8 w / v% of a metal chloride, and 0.001 w / v% to 0.006 w / v% of glucose, wherein the metal chloride is one or more selected from sodium chloride, potassium chloride and calcium chloride.

3. The pharmaceutical composition for soft contact lenses according to claim 1 or 2, wherein the metal chloride is sodium chloride and / or potassium chloride. 4 . The pharmaceutical composition for soft contact lens according to claim 1 , comprising 0.004 w / v % or more of glucose. 5 . The pharmaceutical composition for soft contact lenses according to claim 1 , comprising 0.001 w / v% to 0.005 w / v% inclusive of alkyldiaminoethylglycine hydrochloride and 0.3 w / v% to 0.8 w / v% inclusive of a metal chloride.

6. The pharmaceutical composition for soft contact lenses according to claim 1 or 2, comprising: 0.001 w / v% or more and 0.003 w / v% or less of alkyldiaminoethylglycine hydrochloride, 0.3 w / v% or more and 0.8 w / v% or less of a metal chloride, and 0.002 w / v % or more and 0.006 w / v % or less of glucose.

7. The pharmaceutical composition for soft contact lenses according to claim 1 or 2, further comprising a nonionic surfactant.

8. The pharmaceutical composition for soft contact lens according to claim 1 or 2, further comprising a buffer. 9 . The pharmaceutical composition for soft contact lens according to claim 1 , further comprising a thickener. 10 . The pharmaceutical composition for soft contact lens according to claim 1 , further comprising an amino acid.

11. The pharmaceutical composition for soft contact lenses according to claim 1 or 2, comprising: 0.001 w / v% or more and 0.003 w / v% or less of alkyldiaminoethylglycine hydrochloride, 0.3w / v% or more and 0.8w / v% or less of metal chloride, 0.002 w / v% or more and 0.006 w / v% or less of glucose, 0.005 w / v% or more and 0.05 w / v% or less of polyoxyethylene hydrogenated castor oil, 0.1 w / v% or more and 2.0 w / v% or less of a buffer, 0.05 w / v% or more and 0.5 w / v% or less of a thickener, and 0.05 w / v% or more and 1.0 w / v% or less of amino acids. 12 . The pharmaceutical composition for soft contact lens according to claim 1 , wherein the pH thereof is 5.5 to 8.

0. 13 . The pharmaceutical composition for soft contact lens according to claim 1 , wherein the pH thereof is 6.5 or higher and 7.5 or lower.

Citation Information

Patent Citations

  • Method for improving action and agent for improving action

    JP2001302518A

  • Refreshing agent

    JP2001302545A

  • Pranoprofen-containing formulation

    JP2005336153A

  • Ophthalmic composition

    JP2009046480A

  • Particle beam treatment apparatus

    JP2019217422A